These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1598 related articles for article (PubMed ID: 31884204)

  • 1. Gut microbiome and response to checkpoint inhibitors in non-small cell lung cancer-A review.
    Nagasaka M; Sexton R; Alhasan R; Rahman S; Azmi AS; Sukari A
    Crit Rev Oncol Hematol; 2020 Jan; 145():102841. PubMed ID: 31884204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Commensal microbiota contributes to predicting the response to immune checkpoint inhibitors in non-small-cell lung cancer patients.
    Zhang C; Wang J; Sun Z; Cao Y; Mu Z; Ji X
    Cancer Sci; 2021 Aug; 112(8):3005-3017. PubMed ID: 34028936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of the microbiome on checkpoint inhibitor treatment in patients with non-small cell lung cancer and melanoma.
    Shaikh FY; Gills JJ; Sears CL
    EBioMedicine; 2019 Oct; 48():642-647. PubMed ID: 31597596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Network Analysis of Gut Microbiome and Metabolome to Discover Microbiota-Linked Biomarkers in Patients Affected by Non-Small Cell Lung Cancer.
    Vernocchi P; Gili T; Conte F; Del Chierico F; Conta G; Miccheli A; Botticelli A; Paci P; Caldarelli G; Nuti M; Marchetti P; Putignani L
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33227982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiRNAs and Microbiota in Non-Small Cell Lung Cancer (NSCLC): Implications in Pathogenesis and Potential Role in Predicting Response to ICI Treatment.
    Nucera F; Ruggeri P; Spagnolo CC; Santarpia M; Ieni A; Monaco F; Tuccari G; Pioggia G; Gangemi S
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterisation of gut, lung, and upper airways microbiota in patients with non-small cell lung carcinoma: Study protocol for case-control observational trial.
    Bingula R; Filaire M; Radosevic-Robin N; Berthon JY; Bernalier-Donadille A; Vasson MP; Thivat E; Kwiatkowski F; Filaire E
    Medicine (Baltimore); 2018 Dec; 97(50):e13676. PubMed ID: 30558074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Gut Microbiome from a Biomarker to a Novel Therapeutic Strategy for Immunotherapy Response in Patients with Lung Cancer.
    Duttagupta S; Hakozaki T; Routy B; Messaoudene M
    Curr Oncol; 2023 Oct; 30(11):9406-9427. PubMed ID: 37999101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Association between Immunotherapy with Immune Checkpoint Inhibitors(Anti-PD-1 Antibodies)and Intestinal Microbiota].
    Ozaki Y; Suzuki Y; Nishiyama K; Suzutani T; Suzuki H
    Gan To Kagaku Ryoho; 2021 Sep; 48(9):1096-1099. PubMed ID: 34521783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronological analysis of the gut microbiome for efficacy of atezolizumab-based immunotherapy in non-small cell lung cancer: Protocol for a multicenter prospective observational study.
    Shoji F; Miura N; Tagawa T; Tsukamoto S; Okamoto T; Yamazaki K; Hamatake M; Takeo S
    Thorac Cancer; 2022 Oct; 13(19):2829-2833. PubMed ID: 36063818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome.
    Derosa L; Iebba V; Silva CAC; Piccinno G; Wu G; Lordello L; Routy B; Zhao N; Thelemaque C; Birebent R; Marmorino F; Fidelle M; Messaoudene M; Thomas AM; Zalcman G; Friard S; Mazieres J; Audigier-Valette C; Sibilot DM; Goldwasser F; Scherpereel A; Pegliasco H; Ghiringhelli F; Bouchard N; Sow C; Darik I; Zoppi S; Ly P; Reni A; Daillère R; Deutsch E; Lee KA; Bolte LA; Björk JR; Weersma RK; Barlesi F; Padilha L; Finzel A; Isaksen ML; Escudier B; Albiges L; Planchard D; André F; Cremolini C; Martinez S; Besse B; Zhao L; Segata N; Wojcik J; Kroemer G; Zitvogel L
    Cell; 2024 Jun; 187(13):3373-3389.e16. PubMed ID: 38906102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulating the gut microbiome in non-small cell lung cancer: Challenges and opportunities.
    Bum Lee J; Huang Y; Oya Y; Nutzinger J; LE Ang Y; Sooi K; Chul Cho B; Soo RA
    Lung Cancer; 2024 Aug; 194():107862. PubMed ID: 38959670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of lung and gut microbiota on lung cancer pathogenesis.
    Zhao Y; Liu Y; Li S; Peng Z; Liu X; Chen J; Zheng X
    J Cancer Res Clin Oncol; 2021 Aug; 147(8):2177-2186. PubMed ID: 34018055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interplay between the lung microbiome and lung cancer.
    Mao Q; Jiang F; Yin R; Wang J; Xia W; Dong G; Ma W; Yang Y; Xu L; Hu J
    Cancer Lett; 2018 Feb; 415():40-48. PubMed ID: 29197615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gut microbiome affects the response to immunotherapy in non-small cell lung cancer.
    Ren S; Feng L; Liu H; Mao Y; Yu Z
    Thorac Cancer; 2024 May; 15(14):1149-1163. PubMed ID: 38572783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The Relationship between Gut Microbiome, Immune System, and Cancer].
    Ichikawa M; Sujino T; Kanai T
    Gan To Kagaku Ryoho; 2019 Dec; 46(12):1807-1813. PubMed ID: 31879393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detailed Characterization of the Lung-Gut Microbiome Axis Reveals the Link between PD-L1 and the Microbiome in Non-Small-Cell Lung Cancer Patients.
    Ankudavicius V; Nikitina D; Lukosevicius R; Tilinde D; Salteniene V; Poskiene L; Miliauskas S; Skieceviciene J; Zemaitis M; Kupcinskas J
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The Role of Gut Microbiota in Lung Carcinogenesis and Cancer Immunotherapy].
    Shoji F
    Gan To Kagaku Ryoho; 2024 Jun; 51(6):597-602. PubMed ID: 39009513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gut microbiota and dietary intervention: affecting immunotherapy efficacy in non-small cell lung cancer.
    Xin Y; Liu CG; Zang D; Chen J
    Front Immunol; 2024; 15():1343450. PubMed ID: 38361936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A theoretical model of temperate phages as mediators of gut microbiome dysbiosis.
    Lin DM; Lin HC
    F1000Res; 2019; 8():. PubMed ID: 31316751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gut Microbiota in Lung Cancer: Where Do We Stand?
    Georgiou K; Marinov B; Farooqi AA; Gazouli M
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 80.